Lofexadine: Clonadine in Disguise?
Recently the FDA approved a medication called lofexidine (Lucemyra) for the treatment of opioid withdrawal.
Article provided by Harvard Health Publishing
Lofexidine is in a class of medications called alpha-2-adrenergic agonists, which act on the nervous system and can cause sedation, mild pain relief, and relaxation. This class of medications has been used to treat common medical conditions like high blood pressure or anxiety. They have also been used for decades to ameliorate the symptoms of opioid withdrawal. The more commonly used medication in this group is called clonidine and has been a staple for medically supervised withdrawal. Lofexidine is very similar to clonidine, with one exception: clonidine can cause low blood pressure, which can be a limiting side effect, whereas lofexidine has less of an impact on blood pressure.
How does lofexidine compare to other medications used for withdrawal?
So lofexidine is slightly safer, but does it work? Well, that depends on what you compare it to. Compared to no medication or a placebo, both lofexidine and clonidine are more effective at relieving withdrawal symptoms. However, being better than no treatment is not exactly a winning endorsement. The real question is whether lofexidine is better than standard of care treatment with medications like buprenorphine or methadone. Buprenorphine and methadone are both opioid agonists, meaning they exert activity at the same receptor that all opioids do. This makes them effective at resolving withdrawal symptoms, and also at relieving cravings and reducing the likelihood of relapse and overdose if used in an ongoing way.
When compared to tapering doses of methadone used for medically supervised withdrawal, peak withdrawal severity was worse with lofexidine, meaning people treated with lofexidine instead of methadone were more likely to have severe withdrawal, and reported higher peak scores for withdrawal symptoms. However, overall the withdrawal symptoms resolved sooner with lofexidine compared to methadone, and treatment was shorter.
Can this medication help reduce overdose deaths or help people stay in treatment?
The rub here is that medically supervised withdrawal with methadone or buprenorphine is also not standard of care. A majority of people will relapse after medically supervised withdrawal (often referred to as “detox”). In contrast, being treated long-term with either methadone or buprenorphine as a maintenance medication treatment reduces the risk of relapse and overdose death by more than 50% while increasing the likelihood of staying engaged in treatment.
For example, one seminal paper published in the Lancet randomly assigned a small group of individuals with opioid use disorder to either medically supervised withdrawal followed by a year of intensive psychosocial treatment, or a year of buprenorphine with psychosocial treatment. In the group assigned to medically supervised withdrawal, no one stayed in treatment and 20% were dead at the end of the year. In contrast, in the group assigned to buprenorphine, 75% were abstinent and no one died. These are dramatic differences calling into question any practice of medically supervised withdrawal as an effective intervention for opioid use disorder.
Lofexidine may be an option before starting extended-release naltrexone.
One group of patients who do require medically supervised withdrawal are those who want to start extended-release naltrexone, a third FDA-approved medication for the treatment of opioid use disorder. Unlike methadone and buprenorphine, naltrexone does not activate the opioid receptor, but rather blocks it to prevent the effects of other opioids. People have to be opioid-free for seven to 10 days prior to starting naltrexone, which leads to fewer people being able to successfully start treatment. This is one of the main reasons that extended-release naltrexone is less effective than buprenorphine treatment. However, for patients who choose extended-release naltrexone, effective non-opioid options for withdrawal management are important, and this may be where lofexidine is particularly helpful.
The biggest downside to Lofexidine is its cost. Having just been approved by the FDA in 2018, it is cost-prohibitive for many patients. This is where clonidine makes the most sense. It is inexpensive, readily available, and can be prescribed along side opioid agonists and antagonists like Suboxone, Bunavail and Zubsolv to further reduce withdrawal symptoms, especially when needed most at the very beginning of treatment.
The goal at Suboxone Clinics of Nashville is to provide patients with the easiest transition off of opiates possible, making personalized therapy not only possible, but also much more effective.
If you or someone you know is struggling with opioid addiction, call or text Suboxone Clinics of Nashville today to begin a program of treatment that virtually eliminates withdrawls and cravings, and includes one on one therapy.
Call or text Suboxone Clinics of Nashville today. Get your life back. (615) 431-3701
Leave a Comment